FinnGen research project is an expedition to the frontier of genomics and medicine

Important discoveries could be found on a single sample from any one of Finland’s 500 000 biomedical pioneers.

FinnGen brings together the nation-wide network of Finnish biobanks.

Every Finn can be a part of the FinnGen study by giving a biobank consent.

Samples available

397 800

Samples needed by 2023: 500 000

Current data freeze

224 580

combined genotype and health registry data

Samples from biobanks

The FinnGen study will utilise samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.

Take part

Samples are needed from all over Finland in the thousands, because solutions in the field of personalized healthcare can be found only by looking at large masses. Every Finn can be a part of the FinnGen study by giving a biobank consent.

Everybody benefits

The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.

Collaboration is the key

The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.

Data freeze 2 results and summary statistics released!

Results can be browsed online using the FinnGen web browser and the summary statistics downloaded

This data freeze consists of 96,499 individuals, more than 16 M variants and 1,122 disease endpoints. To get more information about how to access the results and summary statistics, please follow this link:

Access results

Data freeze 2 results and summary statistics released

News

Gene variants that protect against glaucoma identified, opening therapeutic possibilities

An international research collaboration led by researchers from the University of Helsinki and Stanford University has identified rare changes in a gene called ANGPTL7 that lower intraocular pressure and significantly reduce the risk of glaucoma. The results open important new therapeutic possibilities.

Genetic variants in a gene called ANGPTL7 reduce the risk of glaucoma

5.5.2020

FinnGen contributes to COVID-19 host genetics initiative

Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose.

30.4.2020

Tweets by FinnGen_FI